Genome Editing in Drug Discovery. Группа авторов
Читать онлайн книгу.
editorial material in this work has been asserted in accordance with law.
Registered Office John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA
Editorial Office 111 River Street, Hoboken, NJ 07030, USA For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.
Wiley also publishes its books in a variety of electronic formats and by print‐on‐demand. Some content that appears in standard print versions of this book may not be available in other formats.
Limit of Liability/Disclaimer of Warranty In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.
Library of Congress Cataloging‐in‐Publication Data
Names: Maresca, Marcello, editor. | Deswal, Sumit, editor.
Title: Genome editing in drug discovery / Marcello Maresca, AstraZeneca, BioPharmaceuticals R&D, Mölndal, Sweden, Sumit Deswal, AstraZeneca, BioPharmaceuticals R&D, Mö¨lndal, Sweden.
Description: First edition. | Hoboken, NJ : Wiley, 2022. | Includes index.
Identifiers: LCCN 2021025952 (print) | LCCN 2021025953 (ebook) | ISBN 9781119671343 (hardback) | ISBN 9781119671381 (adobe pdf) | ISBN 9781119671398 (epub)
Subjects: LCSH: Drug development. | Genetic engineering.
Classification: LCC RM301.25 .G46 2022 (print) | LCC RM301.25 (ebook) | DDC 615.1/9–dc23
LC record available at https://lccn.loc.gov/2021025952 LC ebook record available at https://lccn.loc.gov/2021025953
Cover image: © Yurchanka Siarhei/Shutterstock
Cover design by Wiley
Preface
The development of CRISPR‐Cas9 for genome engineering has revolutionized the field of genome editing. Many of the cell types and animal models previously very challenging to genetic engineering, can now be engineered with high efficiency and precision using CRISPR‐Cas9‐derived tools. This has led to the development of many novel disease models helping scientists to better understand disease biology as well as providing opportunity to test novel therapeutics. By performing large‐scale functional genomics screens with CRISPR‐Cas9, it is now possible to identify and validate drug targets at a much faster rate and better precision. By assessing gene function comprehensively at large scale and in relevant cell type in early stages, candidate attrition rate is reduced. Genome editing is now part of almost every step in the early part of drug discovery pipeline, from target identification and its validation to mechanistic studies in relevant disease models. In addition, genome editing is used as a promising platform for gene therapy and molecular diagnostics.
We felt a need for a book comprehensively covering these important aspects of genome editing in drug discovery and therapy. Such a book will be of very much interest for those performing genome editing in research institutes or applying genome editing to drug discovery projects at pharmaceutical industries. Such a book will also help students of molecular biology, biotechnology, biochemistry, and pharmaceutical sciences to better understand this very important technology and to exemplify how basic research on a bacterial immune system can have such a big impact in life sciences.
We would like to thank staff at Wiley, especially Jonathan Rose, who first proposed the idea of this book. We would like to thank all the authors who spent their precious time in making this book a reality. Each of the chapter is written by experts on the respective topic working in top pharmaceutical/biotechnology companies or academic institutes.
We would also like to thank colleagues and management at AstraZeneca, Mohammad Bohlooly, Steve Rees, Mike Snowden, and Mene Pangalos for supporting us and allowing us to devote our time for such an academic exercise.
Marcello Maresca and Sumit Deswal
Gothenburg, SwedenApril 2021
List of Abbreviations
AAVAdeno-Associated VirusABEAdenosine Base EditorsADARAdenosine deaminases acting on RNAASOsAntisense oligonucleotidesCARChimeric Antigen ReceptorCas9CRISPR associated protein 9CBECytosine base editorsCRISPRClustered Regularly Interspaced Short Palindromic RepeatsCRISPRaCRISPR activationCRISPRiCRISPR interferencedCas9Dead Cas9DSBDouble strand DNA breakFACSFluorescence-activated cell sortingGEMMGenetically Engineered Mouse ModelHDRHomology Directed RepairiGEMInternational Genetically Engineered MachinesIPRIntellectual Property RightsLNPLipid Nano ParticlesNHEJNon-homologous end joiningPAMProtospacer adjacent motifspegRNAPrime editing guide RNARNAiRNA interferenceRNPRibonucleoproteinsgRNASingle guide RNAsiRNASmall interfering RNAshRNAShort hairpin RNATALENsTranscription activator-like effector nucleasesTGETherapeutic Genome EditingZFNsZinc finger nucleases
List of Contributors
Pinar Akcakaya Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Nina Akrap Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Lukas Badertscher Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Sangsu Bae Department of Chemistry and Research Institute for Convergence of Basic Sciences, Hanyang University, Seoul, South Korea
Fiona M. Behan Functional Genomics, R&D GlaxoSmithKline, Stevenage, UK
Nupur Bhargava Genomics and Molecular Medicine, CSIR‐Institute of Genomics and Integrative Biology, New Delhi, India
Erik Oude Blenke Advanced Drug Delivery, Pharmaceutical Sciences, AstraZeneca R&D, Molndal, Sweden
Alessandro Bonetti Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Molndal, Sweden
Rakesh Kantilal Chandode Gene Therapy, Functional and Mechanistic Safety, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Aaron T. Cheng Functional Genomics, R&D